$9.22
2.54% yesterday
Nasdaq, Jun 27, 10:03 pm CET
ISIN
US67576A1007
Symbol
OCUL
Sector
Industry

Ocular Therapeutix Inc Target price 2025 - Analyst rating & recommendation

Ocular Therapeutix Inc Classifications & Recommendation:

Buy
94%
Hold
6%

Ocular Therapeutix Inc Price Target

Target Price $17.34
Price $9.22
Potential
Number of Estimates 13
13 Analysts have issued a price target Ocular Therapeutix Inc 2026 . The average Ocular Therapeutix Inc target price is $17.34. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 18 analysts: 17 Analysts recommend Ocular Therapeutix Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Ocular Therapeutix Inc stock has an average upside potential 2026 of . Most analysts recommend the Ocular Therapeutix Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 63.72 57.31
9.03% 10.06%
EBITDA Margin -263.65% -328.05%
94.05% 24.42%
Net Margin -303.69% -401.24%
119.81% 32.12%

14 Analysts have issued a sales forecast Ocular Therapeutix Inc 2025 . The average Ocular Therapeutix Inc sales estimate is

$57.3m
Unlock
. This is
3.93% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$72.8m 21.99%
Unlock
, the lowest is
$48.9m 18.02%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $63.7m 9.03%
2025
$57.3m 10.06%
Unlock
2026
$68.8m 20.05%
Unlock
2027
$122m 77.12%
Unlock
2028
$329m 169.73%
Unlock
2029
$642m 95.20%
Unlock
2030
$905m 40.98%
Unlock
2031
$1.2b 30.78%
Unlock
2032
$1.4b 21.39%
Unlock

4 Analysts have issued an Ocular Therapeutix Inc EBITDA forecast 2025. The average Ocular Therapeutix Inc EBITDA estimate is

$-188m
Unlock
. This is
6.11% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-194m 3.35%
Unlock
, the lowest is
$-181m 9.79%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-168m 111.59%
2025
$-188m 11.90%
Unlock
2026
$1.7b 996.29%
Unlock
2027
$-168m 109.99%
Unlock
2028
$-23.2m 86.23%
Unlock
2029
$186m 901.06%
Unlock
2030
$283m 52.52%
Unlock
2031
$371m 31.01%
Unlock
2032
$450m 21.38%
Unlock

EBITDA Margin

2024 -263.65% 94.05%
2025
-328.05% 24.42%
Unlock
2026
2,449.13% 846.57%
Unlock
2027
-138.11% 105.64%
Unlock
2028
-7.05% 94.90%
Unlock
2029
28.93% 510.35%
Unlock
2030
31.30% 8.19%
Unlock
2031
31.36% 0.19%
Unlock
2032
31.35% 0.03%
Unlock

14 Ocular Therapeutix Inc Analysts have issued a net profit forecast 2025. The average Ocular Therapeutix Inc net profit estimate is

$-230m
Unlock
. This is
19.32% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-181m 6.28%
Unlock
, the lowest is
$-248m 28.77%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-194m 139.67%
2025
$-230m 18.83%
Unlock
2026
$-224m 2.52%
Unlock
2027
$-185m 17.44%
Unlock
2028
$-35.7m 80.69%
Unlock
2029
$137m 484.08%
Unlock
2030
$248m 80.47%
Unlock
2031
$387m 56.07%
Unlock
2032
$465m 20.17%
Unlock

Net Margin

2024 -303.69% 119.81%
2025
-401.24% 32.12%
Unlock
2026
-325.79% 18.80%
Unlock
2027
-151.85% 53.39%
Unlock
2028
-10.87% 92.84%
Unlock
2029
21.39% 296.78%
Unlock
2030
27.39% 28.05%
Unlock
2031
32.68% 19.31%
Unlock
2032
32.35% 1.01%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -1.22 -1.44
20.79% 18.03%
P/E negative
EV/Sales 20.73

14 Analysts have issued a Ocular Therapeutix Inc forecast for earnings per share. The average Ocular Therapeutix Inc EPS is

$-1.44
Unlock
. This is
25.22% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-1.13 1.74%
Unlock
, the lowest is
$-1.56 35.65%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-1.22 20.79%
2025
$-1.44 18.03%
Unlock
2026
$-1.41 2.08%
Unlock
2027
$-1.16 17.73%
Unlock
2028
$-0.22 81.03%
Unlock
2029
$0.86 490.91%
Unlock
2030
$1.56 81.40%
Unlock
2031
$2.43 55.77%
Unlock
2032
$2.92 20.16%
Unlock

P/E ratio

Current -8.02 11.60%
2025
-6.39 20.30%
Unlock
2026
-6.55 2.50%
Unlock
2027
-7.94 21.22%
Unlock
2028
-41.09 417.51%
Unlock
2029
10.70 126.04%
Unlock
2030
5.93 44.58%
Unlock
2031
3.80 35.92%
Unlock
2032
3.16 16.84%
Unlock

Based on analysts' sales estimates for 2025, the Ocular Therapeutix Inc stock is valued at an EV/Sales of

20.73
Unlock
and an P/S ratio of
25.63
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 19.92 116.05%
2025
20.73 4.09%
Unlock
2026
17.27 16.70%
Unlock
2027
9.75 43.54%
Unlock
2028
3.62 62.93%
Unlock
2029
1.85 48.77%
Unlock
2030
1.31 29.07%
Unlock
2031
1.00 23.54%
Unlock
2032
0.83 17.61%
Unlock

P/S ratio

Current 24.62 52.23%
2025
25.63 4.09%
Unlock
2026
21.35 16.70%
Unlock
2027
12.05 43.54%
Unlock
2028
4.47 62.93%
Unlock
2029
2.29 48.77%
Unlock
2030
1.62 29.07%
Unlock
2031
1.24 23.54%
Unlock
2032
1.02 17.62%
Unlock

Current Ocular Therapeutix Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked May 29 2025
Needham
Locked
Locked
Locked May 06 2025
Needham
Locked
Locked
Locked Apr 08 2025
William Blair
Locked
Locked
Locked Apr 08 2025
RBC Capital
Locked
Locked
Locked Mar 18 2025
Needham
Locked
Locked
Locked Mar 11 2025
Citizens Capital Markets
Locked
Locked
Locked Mar 04 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
May 29 2025
Locked
Needham:
Locked
Locked
May 06 2025
Locked
Needham:
Locked
Locked
Apr 08 2025
Locked
William Blair:
Locked
Locked
Apr 08 2025
Locked
RBC Capital:
Locked
Locked
Mar 18 2025
Locked
Needham:
Locked
Locked
Mar 11 2025
Locked
Citizens Capital Markets:
Locked
Locked
Mar 04 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today